All In Biotech

Drug Trial Radar · NCT06770881

JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Jan 15, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

  • JSKN033Drug

    JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: Up to 12 months
  2. Maximum Tolerated Dose (MTD) or recommend Phase II dose (RP2D).Time frame: Up to 12 months
  3. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events (TEAE) and Treatment Related Adverse Events (TRAE)Time frame: Throughout the duration of the study, approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.